8-K/A: Beauty Health Company COO Departs, Agrees to Advisory Role with $400,000 Severance

The Beauty Health Company's Chief Operating Officer, Brad Hauser, has mutually terminated his employment, effective April 9, 2024, and will transition to an advisory role until no later than June 30, 2024, with a separation package including $400,000 in severance pay.

Summary

• Brad Hauser's employment as Chief Operating Officer of The Beauty Health Company was mutually terminated without cause on April 9, 2024.
• Mr. Hauser will transition to an advisory role until no later than June 30, 2024, or an earlier date at the company's discretion.
• He will receive his current salary and benefits during the advisory period.
• Mr. Hauser will receive a total separation payment of $400,000, paid bi-weekly over 12 months, starting after his advisory period.
• He will also receive a $85,000 cash payment on June 1, 2024, as part of a prior retention award.
• The company will reimburse the employer portion of COBRA premium payments during the 12-month severance period.
• Mr. Hauser has agreed to a non-competition clause during the severance period, preventing him from working for competitors in the microdermabrasion and hydrodermabrasion industry.
• He has also agreed to provide assistance with transitioning his responsibilities and to cooperate with the company in legal proceedings, with additional compensation for more than 25 hours of legal assistance.

Sentiment

Score: 6

Explanation: The document outlines a planned executive departure with a clear transition plan and severance package. While the departure of a COO is a significant event, the mutual agreement and advisory role suggest a controlled and amicable process. The sentiment is neutral to slightly positive, as the company appears to be managing the transition effectively.

Positives

• The transition of the Chief Operating Officer appears to be amicable, with a mutual agreement in place.
• The company has secured Mr. Hauser's cooperation during the transition period and for potential legal matters.
• The separation agreement includes a non-compete clause, protecting the company's interests.
• Mr. Hauser will provide advisory services during the transition period, ensuring continuity.

Negatives

• The departure of the Chief Operating Officer may create some operational disruption.
• The company will incur significant costs related to the severance package, totaling $485,000 plus COBRA payments.
• The non-compete agreement may limit Mr. Hauser's future employment options.

Risks

• The transition of responsibilities to the Chief Supply Chain and Operations Officer may present challenges.
• There is a risk of potential legal costs if Mr. Hauser's cooperation is required for more than 25 hours.
• The company may face challenges in finding a suitable replacement for the Chief Operating Officer.

Future Outlook

The company will continue to operate with the Chief Supply Chain and Operations Officer taking on additional responsibilities, and will likely seek a replacement for the COO role. The company will also rely on Mr. Hauser's advisory services during the transition period.

Management Comments

• The company and Brad Hauser mutually agreed to terminate his employment as Chief Operating Officer without cause.
• Mr. Hauser agreed to remain with the company in an advisory role until no later than June 30, 2024.
• The company may decide to accelerate the separation date at its sole discretion.
• Mr. Hauser's separation was not a result of any disagreement with the company on any matter relating to the company's financial reporting, operations, policies or practices.

Industry Context

Executive departures are common in the corporate world, and this announcement is not unusual. The transition to an advisory role and the non-compete agreement are standard practices to ensure a smooth transition and protect the company's interests. The beauty and health industry is competitive, and companies often make changes to their leadership teams to adapt to market conditions.

Comparison to Industry Standards

• The severance package provided to Mr. Hauser, including cash severance, retention payment, and COBRA benefits, is generally in line with industry standards for executive departures.
• Non-compete agreements are common in the beauty and health industry to protect intellectual property and competitive advantages, similar to agreements seen in companies like L'Oreal and Estee Lauder.
• The transition to an advisory role is a common practice to ensure a smooth handover of responsibilities, similar to what is seen in other companies undergoing executive changes, such as in the technology sector with companies like Apple and Microsoft.
• The 12-month severance period is a typical duration for executive-level departures, comparable to what is seen in other publicly traded companies.

Management Changes

Stakeholder Impact

• Shareholders may react to the departure of the Chief Operating Officer, but the transition plan and advisory role may mitigate concerns.
• Employees may experience some changes in leadership and responsibilities.
• Customers and suppliers are unlikely to be directly impacted by this change.

Next Steps

• The company will transition Mr. Hauser's responsibilities to the Chief Supply Chain and Operations Officer.
• The company will pay Mr. Hauser his severance and retention payments as outlined in the agreement.
• The company will likely begin the process of finding a replacement for the Chief Operating Officer role.

Key Dates

Keywords

Chief Operating Officer, COO, separation agreement, severance, non-compete, advisory role, transition, Hydrafacial, Beauty Health Company, executive departure